Evidence map›Paper›PMID 39927763›Full record

ArticlemSphere2025

Relevance of oncobiome in breast cancer evolution in an Argentine cohort.

Leonardo Néstor Rubén Dandeu, Joel Lachovsky, Sofía Sidlik, Pablo Marenco, Daniela Orschanski, Pablo Aguilera, Martín Vázquez, María Del Pilar Carballo, Elmer Fernández, Alberto Penas-Steinhardt and 2 more

Abstract read
In one paragraph

Article in mSphere, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Leonardo Néstor Rubén DandeuLaboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Fundación IBYME, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Joel LachovskyLaboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Fundación IBYME, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Sofía SidlikLaboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Fundación IBYME, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Pablo MarencoInstituto de Oncología Ángel H Roffo, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Daniela OrschanskiFundación para el Progreso de la Medicina, Córdoba, Argentina.
Pablo AguileraDepartamento de Ciencias Aplicadas y Tecnología, Universidad Nacional de Moreno, Moreno, Argentina.
Martín VázquezInstituto Héritas, Rosario, Argentina.
María Del Pilar CarballoInstituto de Oncología Ángel H Roffo, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Elmer FernándezFundación para el Progreso de la Medicina, Córdoba, Argentina.
Alberto Penas-SteinhardtDepartamento de Ciencias Básicas, Laboratorio de Genómica Computacional (GEC-UNLu), Universidad Nacional de Luján, Luján, Argentina.
Norma Alejandra ChasseingLaboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Fundación IBYME, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.
Vivian LabovskyLaboratorio de Inmunohematología, Instituto de Biología y Medicina Experimental (IBYME), Fundación IBYME, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina.ORCID 0000-0001-7255-1926

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer is the leading cause of cancer deaths in women worldwide, with about 20,000 cases annually in Argentina. While age, diet, and genetics are known risk factors, most breast cancer cases have unknown causes, necessitating the discovery of new risk factors. The aim of this study was the analysis of the prognostic relevance of the oncobiome in Argentinean breast cancer patients. Sequencing of the V4 region 16S rRNA gene was performed on 34 primary breast tumor samples, using bioinformatic and statistical analyses to identify bacteria and hypothetical pathways. Each sample presented a unique microbial profile, with IMPORTANCE: This is the first study to investigate the relevance of the oncobiome in the evolution of breast cancer in a cohort of Argentine patients. It also highlights the need for further research in this area to improve our understanding of the role of the microbiome in this disease and potentially identify new therapeutic targets or prognostic indicators. Understanding the complex interaction between the microbiome, the tumor microenvironment, and the pathogenesis of breast cancer holds the promise of more personalized and effective treatment approaches in the future.

Indexed as

BacteriaBreast NeoplasmsMicrobiotaAdultAgedArgentinaCohort StudiesDisease ProgressionFemaleHumansMiddle AgedPrognosisRNA, Ribosomal, 16SRNA, Ribosomal, 16Sbreast canceroncobiomeprogression diseasetumor microenvironment

Identifiers

PMID39927763
PMCPMC11934308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.